STAAR Surgical’s largest shareholder has mentioned it plans to vote in opposition to Alcon’s proposed $1.5bn takeover of the ailing eye specialist.
Broadwood Companions, which owns 27.3% of STAAR’s frequent shares, mentioned the transaction, introduced final month, suffered from “a number of course of and valuation deficiencies”.
The funding agency expressed disappointment over the actions of STAAR’s board, claiming it had did not pursue an “satisfactory” sale course of. In keeping with Broadwood, STAAR’s board additionally displayed “intransigence” in relation to Broadwood’s books and document demand, stating it had acquired no paperwork since making the request greater than three weeks in the past.
STAAR’s Q1 2025 financials revealed a forty five% decline in gross sales to $42.6m, down from $77.4m in Q1 2024, with the US-based firm mainly attributing the sharp decline to weakened demand in China and extra headwinds as a consequence of authorities initiatives within the nation affecting gadget procurement.
Broadwood’s major level of competition pertains to the proposed monetary phrases of Alcon’s acquisition. The shareholder identified that Alcon beforehand supplied $55 per share for STAAR when it moved to amass the corporate in October 2024 – a value “far above” the present supply of $28 per share.
Alcon subsequently pulled again from its preliminary supply after studying that STAAR was going through stock administration challenges, with the revelation giving the Swiss firm pause over STAAR’s short-term efficiency and stability.
Nonetheless, Broadwood highlighted that these earlier challenges had now been addressed, and that STAAR had improved its value self-discipline, a decision Broadwood now expects will result in a “sharp rebound” in STAAR’s income and earnings within the coming quarters.
Bolstering these claims, Broadwood additionally highlighted that the outcomes of a scientific trial [NCT06700460] evaluating Alcon’s LASIK platform to STAAR’s EVO Implantable Collamer Lens (ICL) for treating astigmatism are quickly due for publication. The shareholder mentioned the trial outcomes might have “important implications” for the aggressive positioning of the EVO ICL relative to LASIK, and in flip to STAAR’s “development prospects and strategic worth” to potential acquirers inside the ophthalmic merchandise business.
The corporate mentioned in a press release: “Broadwood is worried that stockholders at the moment are being requested to just accept inferior phrases, even if the challenges that adopted Alcon’s preliminary bid have been considerably resolved.”
In closing, Broadwood reiterated that it held “critical considerations” concerning the total equity and integrity of the gross sales course of, stating: “Along with the inadequate merger consideration, [the factors at hand] lead us to imagine that the acquisition is just not in the most effective curiosity of STAAR’s shareholders. Accordingly, Broadwood intends to vote in opposition to the acquisition and asks the board to right away rethink its suggestion thereof.”